Pharmaceuticals group GlaxoSmithKline has revealed that a clinical trial for its lung cancer treatment failed to meet its main objectives.Analysis of the MAGRIT placebo-controlled trial, a phase III trial of its MAGE-A3 cancer immunotherapeutic in non-small cell lung cancer (NSCLC) patients, showed that it did not meet its first or second co-primary endpoints.MAGE-A3 is a tumour-specific antigen seen in a variety of cancers but not in normal cells. In NSCLC, it is expressed in approximately one third of tumours in patients diagnosed with Stage IB-IIIA disease.GSK explained that the treatment failed to significantly extend disease-free survival when compared to the placebo in either the overall MAGE-A3 positive population (first co-primary endpoint) or in those MAGE-A3-positive patients who did not receive chemotherapy (second co-primary endpoint).Nevertheless, the firm said it will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population. Results from a final analysis are expected in 2015.Vincent Brichard, Senior Vice-President & Head of Immunotherapeutics at GSK Vaccines, said he was "disappointed that the trial did not demonstrate a benefit for overall MAGE-A3 positive patient population".However, he added: "We remain committed to the effort to identify a sub-population of NSCLC patients who may benefit from this investigational treatment."GSK was trading 1.2% lower at 1,636p by 08:18.BC